Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Tanabe Clinches EU Approval for Parkinson’s Drug Onerji
Tanabe Pharma said on April 30 that it has won EU regulatory approval for Onerji (levodopa + carbidopa), a Parkinson’s disease therapy developed by its wholly owned Israeli subsidiary NeuroDerm. The green light was granted by the European Commission, dated…
To read the full story
Related Article
- FDA Again Rejects Mitsubishi Tanabe’s Parkinson’s Drug
October 24, 2025
- Mitsubishi Re-Files NeuroDerm’s Parkinson’s Drug in US
May 30, 2025
- Mitsubishi Tanabe’s Parkinson’s Drug Accepted for EMA Review
February 25, 2025
- Mitsubishi to Take Another Stab at Parkinson’s Drug Submission in US
November 5, 2024
- US FDA Snubs Mitsubishi Tanabe’s Parkinson’s Drug
June 12, 2024
- NeuroDerm’s Parkinson’s Med Hits Main Goal in PIII
January 11, 2023
BUSINESS
- US FDA Accepts Shionogi’s Pediatric Fetroja Filing
July 21, 2026
- Kaken’s Vascular Malformation Drug Shows Efficacy in Japan PIII
July 21, 2026
- J&J’s Carvykti Wins Japan Approval for Earlier-Line MM Use
July 21, 2026
- Merck Biopharma Starts Japan PIII Trial of LH/FSH Combo
July 17, 2026
- Eisai’s Dayvigo Accepted for EMA Review
July 17, 2026
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…